@article{d6753d70cff14aad878c16fff4ffb763,
title = "In vivo reprogramming for brain and spinal cord repair",
abstract = "Cell reprogramming technologies have enabled the generation of various specific cell types including neurons from readily accessible patient cells, such as skin fibroblasts, providing an intriguing novel cell source for autologous cell transplantation. However, cell transplantation faces several difficult hurdles such as cell production and purification, long-term survival, and functional integration after transplantation. Recently, in vivo reprogramming, which makes use of endogenous cells for regeneration purpose, emerged as a new approach to circumvent cell transplantation. There has been evidence for in vivo reprogramming in the mouse pancreas, heart, and brain and spinal cord with various degrees of success. This mini review summarizes the latest developments presented in the first symposium on in vivo reprogramming glial cells into functional neurons in the brain and spinal cord, held at the 2014 annual meeting of the Society for Neuroscience in Washington, DC.",
keywords = "Astrocyte, Brain repair, In vivo, NG2 cell, Neuron, Reprogramming",
author = "Gong Chen and Marius Wernig and Benedikt Berninger and Masato Nakafuku and Malin Parmar and Zhang, {Chun Li}",
note = "Funding Information: This work was supported by grants from the NIH (MH083911 and AG045656), the Alzheimer{\textquoteright}s Association (ZEN-15-321972), and a Stem Cell Endowment fund from Penn State University to G.C. (G.C. is Verne M. Willa-man Chair in Life Sciences at Penn State University); NIH grants NS088095 and NS070981, the Welch Foundation (I-1724), and the Decherd Foundation to Funding Information: This work was supported by grants from the NIH (MH083911 and AG045656), the Alzheimer{\textquoteright}s Association (ZEN-15-321972), and a Stem Cell Endowment fund from Penn State University to G.C. (G.C. is Verne M. Willaman Chair in Life Sciences at Penn State University); NIH grants NS088095 and NS070981, the Welch Foundation (I-1724), and the Decherd Foundation to C.-L.Z.; NIH/NINDS grant 2R01NS069893 to M.N.; the European Research Council under the European Union{\textquoteright}s 7th Framework Programme (FP/2007- 2013) /ERC Grant Agreement n. 309712 and Swedish Research Council (VR, K2014-61X-20391-08-4) to M.P.; the Deutsche Forschungsgemeinschaft (BE 4182/4-1) and the Belgian Science Policy Office P7/20 (Wibrain) to B.B.; and NIH grants R01MH092931 and RF1 AG048131, the California Institute of Regenerative Medicine grant RB5-07466, and the New York Stem Cell Foundation to M.W. (M.W. is a Tashia and John Morgridge Faculty Scholar, Child Health Research Institute at Stanford and a New York Stem Cell Foundation- Robertson Investigator). Funding Information: C.-L.Z.; NIH/NINDS grant 2R01NS069893 to M.N.; the European Research Council under the European Union{\textquoteright}s 7th Framework Programme (FP/2007-2013) /ERC Grant Agreement n. 309712 and Swedish Research Council (VR, K2014-61X-20391-08-4) to M.P.; the Deutsche Forschungsgemeinschaft (BE 4182/4-1) and the Belgian Science Policy Office P7/20 (Wibrain) to B.B.; and NIH grants R01MH092931 and RF1 AG048131, the California Institute of Regenerative Medicine grant RB5-07466, and the New York Stem Cell Foundation to M.W. (M.W. is a Tashia and John Morgridge Faculty Scholar, Child Health Research Institute at Stanford and a New York Stem Cell Foundation-Robertson Investigator). Publisher Copyright: {\textcopyright} 2015 Chen et al.",
year = "2015",
doi = "10.1523/ENEURO.0106-15.2015",
language = "English (US)",
volume = "2",
journal = "eNeuro",
issn = "2373-2822",
publisher = "Society for Neuroscience",
number = "5",
}